Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3136 - Novel genetic marker of diarrhea in renal cell carcinoma patients treated with sorafenib


10 Oct 2016


Poster display


Federico Innocenti


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


F. Innocenti1, A. Karabinos2, A. Etheridge2, C. Pena3, D. Crona4

Author affiliations

  • 1 Eshelman School Of Pharmacy, University of North Carolina - Chapel Hill, 27599 - Chapel Hill/US
  • 2 Eshelman School Of Pharmacy, University of North Carolina - Chapel Hill, Chapel Hill/US
  • 3 Clinical Pharmacology, Oncology, Bayer Healthcare Pharmaceuticals, Whippany/US
  • 4 Eshelman School Of Pharmacy, University of North Carolina - Chapel Hill, 9 - Chapel Hill/US


Abstract 3136


Sorafenib, the first oral anti-angiogenic multikinase inhibitor, is primarily used in the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma, and thyroid cancer. Common toxicities experienced by patients treated with sorafenib limit its use and affect adherence to treatment, reducing sorafenib efficacy. No biomarkers are currently available to identify patients at risk of toxicity.


Metastatic RCC (mRCC) patients (n = 153) treated with sorafenib, as part of the TARGET study (Escudier B, N Engl J Med. 2007), were genotyped for common germline DNA variants in 56 candidate genes. Associations between 5846 variants and grade 2-4 toxicities were analyzed. Patients treated for ≤28 days were excluded. Toxicities included diarrhea, hypertension, hand-foot skin reaction, and/or rash or desquamation. For each toxicity, the worst grade event for each patient was used. After linkage disequilibrium-based pruning, 685 variants were utilized for analysis via a chi-squared test.


Out of 153 patients, 28 (18%) experienced grade ≥2 diarrhea. The A allele of rs917881 (G > A) in the epidermal growth factor receptor (EGFR) gene was associated with an increased risk of grade ≥2 diarrhea (p = 0.00006, p = 0.04 after Bonferroni's correction, odds ratio 3.6). The frequency of grade ≥2 diarrhea was 50% (3/6) in AA, 33% (15/45) in GA, and 10% (10/102) in GG patients. The frequency of grade 3 diarrhea was 8% (4/51) in patients with the A allele (AA + GA) versus 2% (2/102) in patients with the GG genotype. No other variants were significantly associated with sorafenib toxicity after Bonferroni correction.


To our knowledge, this is the first reported study of a genetic basis of sorafenib toxicity. rs917881 is a common intronic variant (17% allele frequency) in EGFR. RAF kinase, a critical component of the EGFR signaling pathway, is a known target of sorafenib. Patients with the rs917881 A allele treated with sorafenib may be at an increased risk for diarrhea as a result of decreased EGFR expression potentiated by sorafenib-induced inhibition of the RAF/MEK/Erk pathway, which regulates chloride secretion (Keely SJ, J Biol Chem. 1998). Replication analyses in additional patient cohorts and functional studies are ongoing.

Clinical trial identification


Legal entity responsible for the study

University of North Carolina at Chapel Hill


National Institutes of Health


C. Pena: Employee of and owns stock in Bayer Healthcare Pharmaceuticals. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings